Please assess the completion status of the following clinical trial:

Trial Title: First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed colorectal adenocarcinoma~* Unresectable and measurable metastatic disease (RECIST criteria)~* Male or female, aged \> 18 years and ≤ 75 years~* ECOG Performance Status (PS) \< 2 if aged \< 71 years~* ECOG PS = 0 if aged 71-75 years~* Life expectancy of more than 3 months~* Adequate haematological function: ANC ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L, Hb ≥ 9 g/dL~* INR ≤ 1.5 and aPTT ≤ 1.5 x ULN within 7 days prior to starting study treatment~* Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases \< 5 x ULN)~* Serum Creatinine ≤ 1.5 x ULN~* Urine dipstick for proteinuria \< 2+. If urine dipstick is ≥ 2+, 24- hour urine must demonstrate ≤ 1 g of protein in 24 hours~* Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse~* At least 6 weeks from prior radiotherapy and 4 weeks from surgery~Exclusion Criteria:~* Prior palliative chemotherapy~* Prior treatment with bevacizumab~* Bowel obstruction (or subobstruction)~* History of inflammatory enteropathy or extensive intestinal resection (\> hemicolectomy or extensive small intestine resection with chronic diarrhea)~* Symptomatic peripheral neuropathy \> 2 grade NCIC-CTG criteria~* Presence or history of CNS metastasis~* Active uncontrolled infections~* Active disseminated intravascular coagulation~* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment, or anticipation of the need for major surgery during the course of the study~* Central Venous Access Device (CVAD) for chemotherapy administration inserted within 2 days prior to study treatment start~* Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix~* Clinically significant cardiovascular disease, for example cerebrovascular accidents (CVA) (≤ 6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia~* Uncontrolled hypertension~* 24-hour urine protein \> 1 g if dipstick \> 2+~* History of thromboembolic or hemorrhagic events within 6 months prior to treatment~* Evidence of bleeding diathesis or coagulopathy~* Serious, non healing wound/ulcer or serious bone fracture~* No therapeutic anticoagulation or antiplatelet agents or NSAID with anti-platelet activity (aspirin ≤ 325 mg/day allowed)~* Pregnancy or lactation~* Fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOXIRI plus bevacizumab (Type: EXPERIMENTAL): BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).